Effect of Raltegravir on the Total and Unintegrated Proviral HIV Dna during Raltegravir-Based Haart

Hazuda D.J. , Felock P. , Witmer M. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646–650.

Steigbigel R.T. , Cooper D.A. , Kumar P.N. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339–354.

Cooper D.A. , Steigbigel R.T. , Gatell J.M. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355–365.

Markowitz M. , Nguyen B.Y. , Gotuzzo E. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46: 125–133.

Lennox J.L. , DeJesus E. , Lazzarin A. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet 2009; 374: 796–806.

US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents – working group of the Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Accessed 20 December 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Raltegravir tablets. FDA Advisory Committee Meeting briefing document. Background package 2007. Merck & Co. Inc. Whitehouse Station, NJ, USA.

Wenning L. , Nguyen B-Y , Sun X. Pharmacokinetic/ pharmacodynamic (PK/PD analyses for raltegravir in phase II and III studies in treatment experienced HIV infected patients. 9th International Workshop Clinical Pharmacology of HIV Therapy. 7–9 April 2008, New Orleans, LA, USA. Abstract H-4054.

Johnson V.A. , Brun-Vezinet F. , Clotet B. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17: 138–145.

Viard J.P. , Burgard M. , Hubert J.B. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004; 18: 45–49.

Sharkey M.E. , Teo I. , Greenough T. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000; 6: 76–81.

Sozzi G. , Conte D. , Leon M. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003; 21: 3902–3908.

D'Avolio A. , Baietto L. , Siccardi M. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new non nucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662–669.

Burgard M. , Boufassa F. , Viard J.P. Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients. AIDS 2009; 23: 2165–2171.

Gandhi R.T. , Bosch R.J. , Aga E. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010; 201: 293–296.

Re M.C. , Vitone F. , Biagetti C. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients. Clin Microbiol Infect 2010; 16: 640–646.

Buzón M.J. , Massanella M. , Llibre J.M. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16: 460–465.

Delaugerre C. , Charreau I. , Braun J. the ANRS 138 study group. Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. AIDS 2010; 24: 2391–2395.

Goffinet C. , Allespach I. , Oberbremer L. Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. J Virol 2009; 83: 7706–7717.

Reigadas S. , Andréola M.L. , Wittkop L. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells. J Antimicrob Chemother 2010; 65: 434–437.

Butler S.L. , Johnson E.P. , Bushman F.D. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002; 76: 3739–3747.

Li L. , Olvera J.M. , Yoder K.E. Bushman. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J 2001; 20: 3272–3281.

Pierson T.C. , Kieffer T.L. , Ruff C.T. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002; 76: 4138–4144.

Huang L.C. , Clarkin K.C. , Wahl G.M. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A 1996; 93: 4827–4832.

Li L. , Olvera J.M. , Yoder K.E. Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J 2001; 20: 3272–3281.

Venzke S. , Keppler O.T. The role of macrophages in HIV infection and persistence. Expert Rev Clin Immunol 2006; 2: 613–626.

Garaci E. , Aquaro S. , Lapenta C. Anti-nerve growth factor Ab abrogates macrophage-mediated HIV-1 infection and depletion of CD4⁺ T lymphocytes in hu-SCID mice. Proc Natl Acad Sci U S A 2003; 100: 8927–8932.

Han Y. , Wind-Rotolo M. , Yang H.C. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 2007; 5: 95–106.

Murray J.M. , Emery S. , Kelleher A.D. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21: 2315–2321.